Details of the Drug

General Information of Drug (ID: DM0VBRG)

• Drug Name: TAK-981
• Synonyms: TAK-981; 1858276-04-6; UNII-XQ43H3V6M1; XQ43H3V6M1; Sumoylation inhibitor TAK-981; SCHEMBL17398333; LXRZVMYMQHNYJB-UNXOBOICSA-N; TAK 981; TAK981; EX-A3291; BCP30806; HY-111789; CS-0091878

Indication

Disease Entry	ICD 11	Status	REF
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 1	[1]

• Drug Type: Small molecular drug
• Chemical Identifiers:
  Formula: C25H28ClN5O5S2
  Canonical SMILES: CC1=C(C=C(S1)C(=O)C2=CN=CN=C2NC3CC(C(C3)O)COS(=O)(=O)N)C4C5=C(CCN4)C=CC(=C5)Cl
  InChI: InChI=1S/C25H28ClN5O5S2/c1-13-18(23-19-7-16(26)3-2-14(19)4-5-29-23)9-22(37-13)24(33)20-10-28-12-30-25(20)31-17-6-15(21(32)8-17)11-36-38(27,34)35/h2-3,7,9-10,12,15,17,21,23,29,32H,4-6,8,11H2,1H3,(H2,27,34,35)(H,28,30,31)/t15-,17-,21+,23+/m1/s1
  InChIKey: LXRZVMYMQHNYJB-UNXOBOICSA-N
• Cross-matching ID:
  PubChem CID: 118628567
  ChEBI ID: CHEMBL4862901
  CAS Number: 1858276-04-6
  UNII: XQ43H3V6M1
  DrugBank ID: DB16406
  TTD ID: D05LBN
• Drug-Molecule Activity Atlas (DMA)NEW: Click to Jump to the Detailed DMA Information of This Drug

References

• [1] ClinicalTrials.gov (NCT03648372) A Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19). U.S. National Institutes of Health.